Award to fund development milestones amount.

No definition available.

Name:	elox_AwardToFundDevelopmentMilestonesAmount
Namespace Prefix:	elox_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Funding award amount received.

+ References

No definition available.

+ Details

Name:	elox_FundingAwardAmountReceived
Namespace Prefix:	elox_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number Of Times Amount Of Funds Received

+ References

No definition available.

+ Details

Name:	elox_NumberOfTimesAmountOfFundsReceived
Namespace Prefix:	elox_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage Of Consideration Received For Disposition Event

+ References

No definition available.

+ Details

Name:	elox_PercentageOfConsiderationReceivedForDispositionEvent
Namespace Prefix:	elox_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of sale or license event.

+ References

No definition available.

+ Details

Name:	elox_PercentageOfSaleOrLicenseEvent
Namespace Prefix:	elox_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Related party transaction percentage of expenses.

+ References

No definition available.

+ Details

Name:	elox_RelatedPartyTransactionPercentageOfExpenses
Namespace Prefix:	elox_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Remaining amount of award payable upon achievement certain clinical development milestones.

+ References

No definition available.

+ Details

Name:	elox_RemainingAmountOfAwardPayableUponAchievementCertainClinicalDevelopmentMilestones
Namespace Prefix:	elox_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalties Percentage Of Net Sales Based On Actual Amount Of Funding

+ References

No definition available.

+ Details

Name:	elox_RoyaltiesPercentageOfNetSalesBasedOnActualAmountOfFunding
Namespace Prefix:	elox_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a)(5))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12)(b)(3))
-URI https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996

+ Details

Name:	us-gaap_DueToAffiliateCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 15
-URI https://asc.fasb.org/subtopic&trid=2229187

+ Details

Name:	us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=elox_TwoThousandNineteenCysticFibrosisFoundationAwardMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=elox_TwoThousandTwentyTwoCysticFibrosisFoundationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=elox_EloxLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=elox_EloxCysticFibrosisFoundationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=elox_EloxPhaseTwoClinicalDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=elox_TwoThousandTwentyOneCysticFibrosisFoundationAwardMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Advances From Collaboration Partners, Legal and Other Contingencies - Additional Information (Detail) $ in Thousands	1 Months Ended		3 Months Ended
	Mar. 31, 2022 USD ($)	May 31, 2021 USD ($)	Mar. 31, 2023 USD ($) Time	Dec. 31, 2022 USD ($)
Advances from collaboration partners			$ 12,535	$ 12,535
Royalties percentage of net sales based on actual amount of funding			6.00%
Maximum [Member]
Related party transaction percentage of expenses			5.00%
Two Thousand Nineteen Cystic Fibrosis Foundation Award [Member]
Advances from collaboration partners			$ 11,900	11,900
Two Thousand Nineteen Cystic Fibrosis Foundation Award [Member] \| Maximum [Member]
Funding award amount received			$ 3,600
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member]
Number of times amount of funds received \| Time			3
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member] \| Elox - Liabilities [Member]
Advances from collaboration partners			$ 58	45
Embedded derivative, gain (loss) on embedded derivative, net			$ 13
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member] \| Elox - Cystic Fibrosis Foundation [Member]
Percentage Of Consideration Received For Disposition Event			10.00%
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member] \| Elox - Cystic Fibrosis Foundation [Member] \| Elox - Phase Two Clinical Development [Member]
Remaining amount of award payable upon achievement certain clinical development milestones			$ 7,400
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member] \| Elox - Cystic Fibrosis Foundation [Member] \| Elox - Phase Two Clinical Development [Member] \| Maximum [Member]
Award to fund development milestones	$ 15,900
Two Thousand Twenty One Cystic Fibrosis Foundation Award [Member]
Advances from collaboration partners			$ 600	$ 600
Two Thousand Twenty One Cystic Fibrosis Foundation Award [Member] \| Maximum [Member]
Funding award amount received		$ 2,600
Two Thousand Twenty One Cystic Fibrosis Foundation Award [Member] \| Elox - Cystic Fibrosis Foundation [Member]
Percentage Of Consideration Received For Disposition Event			20.00%
Percentage of sale or license event			10.00%